A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma


Full Title

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma


This study has two parts. The purpose of the phase IA part of the study is to find the highest dose of the investigational drug TTI-622 that can be given safely in patients with non-Hodgkin lymphoma or Hodgkin lymphoma that continues to grow or came back after prior treatment.

In the phase IB part, researchers will assess the safety of combining TTI-622 with standard treatments. Patients with non-Hodgkin lymphoma will receive TTI-622 with rituximab, those with Hodgkin lymphoma will receive TTI-622 with nivolumab, and patients with multiple myeloma will receive TTI-622 with carfilzomib.

TTI-622 is a fusion of two proteins. One binds with other proteins found on the surface of certain immune cells. The other protein interacts with a protein on cancer cells called CD47, which cancer cells use to hide from the immune system. Blocking CD47 with TTI-622 may help the immune system find and destroy cancer cells. TTI-622 is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have non-Hodgkin lymphoma, Hodgkin lymphoma, or multiple myeloma that continues to grow or came back after prior treatment.
  • Patients should recover from the serious side effects of previous therapies before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alexander Lesokhin at 212-639-3069.





Disease Status

Relapsed or Refractory